Santen Inc. clinical trials

A subsidiary of Santen Pharmaceutical Co., Ltd.

The registry lists 54 studies whose lead sponsor is Santen Inc.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 7, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 54. List all 54 → · All Santen Pharmaceutical Co., Ltd. studies →

• PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control GroupRecruitingNCT07235592

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.RecruitingNCT06514612Phase 3

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)CompletedNCT05376176Phase 2

  Sponsor listed in the registry: Santen Inc.

• Observational Survey Study on the Impact of Myopia and Its Complications on Quality of Life.CompletedNCT06912802

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or KeratoconjunctivitisCompletedNCT04701086Not applicable

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or KeratoconjunctivitisActive, not recruitingNCT04685109Not applicable

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)CompletedNCT04144413Phase 3

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With PresbyopiaCompletedNCT05665387Phase 2

  Sponsor listed in the registry: Santen Inc.

• A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT04133311Phase 3

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe KeratitisCompletedNCT03237936Phase 4

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the EyeTerminatedNCT03711929Phase 3

  Sponsor listed in the registry: Santen Inc.

• A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 StudyCompletedNCT03691649Phase 3

  Sponsor listed in the registry: Santen Inc.

• DE-117 Spectrum 5 StudyCompletedNCT03697811Phase 3

  Sponsor listed in the registry: Santen Inc.

• A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 StudyCompletedNCT03691662Phase 3

  Sponsor listed in the registry: Santen Inc.

• Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT04742283Phase 2

  Sponsor listed in the registry: Santen Inc.

• Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal KeratoconjunctivitisCompletedNCT01751126Phase 3

  Sponsor listed in the registry: Santen SAS · First submitted after Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)CompletedNCT00328653Phase 2/3

  Sponsor listed in the registry: Santen SAS · First submitted before Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration SubjectsCompletedNCT03211234Phase 2

  Sponsor listed in the registry: Santen Inc.

• A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel StudyCompletedNCT03216902Phase 2

  Sponsor listed in the registry: Santen Inc.

• Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6CompletedNCT03858894Phase 2

  Sponsor listed in the registry: Santen Inc.

• A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development ProgramCompletedNCT02251938Phase 3

  Sponsor listed in the registry: Santen Inc.

• A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular DegenerationCompletedNCT02555306Phase 1/2

  Sponsor listed in the registry: Santen Inc.

• Study Assessing Double-masked Uveitis TreatmentCompletedNCT01358266Phase 3

  Sponsor listed in the registry: Santen Inc.

• Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT01868126Phase 2

  Sponsor listed in the registry: Santen Inc.

• A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular DegenerationCompletedNCT02022501Phase 1/2

  Sponsor listed in the registry: Santen Inc.

• A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTCompletedNCT01654484Phase 1/2

  Sponsor listed in the registry: Santen Inc.

• Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT02179008Phase 2

  Sponsor listed in the registry: Santen Inc.

• A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular DegenerationCompletedNCT02401945Phase 2

  Sponsor listed in the registry: Santen Inc.

• A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular HypertensionCompletedNCT02102750Phase 1

  Sponsor listed in the registry: Santen Oy · Santen Oy — acquired company within the Santen Pharmaceutical Co., Ltd. group

• Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface DiseaseCompletedNCT01254370Phase 2

  Sponsor listed in the registry: Santen SAS · First submitted before Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry EyeCompletedNCT00739349Phase 2

  Sponsor listed in the registry: Santen SAS · First submitted before Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic RetinopathyCompletedNCT00665106Phase 1

  Sponsor listed in the registry: Santen SAS · First submitted before Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye DiseaseCompletedNCT01239069Phase 2

  Sponsor listed in the registry: Santen Inc.

• Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye DropsCompletedNCT01087671Phase 3

  Sponsor listed in the registry: Santen Oy · Santen Oy — acquired company within the Santen Pharmaceutical Co., Ltd. group

• Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against MonotherapiesCompletedNCT01292460Phase 3

  Sponsor listed in the registry: Santen Oy · Santen Oy — acquired company within the Santen Pharmaceutical Co., Ltd. group

• Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular DegenerationTerminatedNCT00712491Phase 1/2

  Sponsor listed in the registry: Santen Inc.

• A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) ModelCompletedNCT00814944Phase 2

  Sponsor listed in the registry: Santen Inc.

• Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular EdemaCompletedNCT00656643Phase 2

  Sponsor listed in the registry: Santen Inc.

• Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular DegenerationTerminatedNCT00766337Phase 2

  Sponsor listed in the registry: Santen Inc.

• A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye PatientsCompletedNCT01468168Phase 2

  Sponsor listed in the registry: Santen Inc.

• Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01279083Phase 1/2

  Sponsor listed in the registry: Santen Inc.

• Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant AdministrationsCompletedNCT01306461Phase 3

  Sponsor listed in the registry: Santen Oy · Santen Oy — acquired company within the Santen Pharmaceutical Co., Ltd. group

• Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye DropsCompletedNCT01434888Phase 1

  Sponsor listed in the registry: Santen Oy · Santen Oy — acquired company within the Santen Pharmaceutical Co., Ltd. group

• Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular HypertensionCompletedNCT00868894Phase 1/2

  Sponsor listed in the registry: Santen Inc.

• Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular HypertensionCompletedNCT00650338Phase 2

  Sponsor listed in the registry: Santen Inc.

• Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye PatientsCompletedNCT01118754Phase 1/2

  Sponsor listed in the registry: Santen Inc.

• Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved FormulationCompletedNCT00918346Phase 3

  Sponsor listed in the registry: Santen Oy · Santen Oy — acquired company within the Santen Pharmaceutical Co., Ltd. group

• Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic RetinopathyCompletedNCT00401115Phase 1

  Sponsor listed in the registry: Santen Inc.

• Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye SyndromeCompletedNCT00814515Phase 3

  Sponsor listed in the registry: Santen SAS · First submitted before Santen SAS became part of Santen Pharmaceutical Co., Ltd.

• Interaction Study of Timolol Eye Drops and Paroxetine CapsulesCompletedNCT00879099Phase 1

  Sponsor listed in the registry: Santen Oy · Santen Oy — acquired company within the Santen Pharmaceutical Co., Ltd. group